News | September 13, 2011

Costs, Mortality Skyrocket Following Infection in Cardiac Device Recipients

September 13, 2011 – A new study finds that infections following cardiac device implantations or replacement result in extremely high costs, both financially and in terms of patient mortality, even months after affected patients return home. Infections associated with pacemakers and defibrillators led to 4.8 to 7.7-fold increases in admission mortality, 1.6 to 2.1-fold increases long term mortality, 2.5 to 4-fold increases in hospital length of stay, and 1.4 to 1.8-fold increases in cost compared to pacemaker and defibrillator implantations without infection. Surprisingly, more than one-third of the excess mortality occurred after hospital discharge.

These findings, from a study of more than 200,000 Medicare beneficiaries receiving pacemaker and defibrillator implantations, with and without infection, were published today, via ePub, by the Archives of Internal Medicine. The study risk-adjusted the outcomes for comorbidities and demographic characteristics.

“While healthcare reform has been a subject of intense debate lately, unfortunately, most attention and work has been centered on payment or insurance reform and little attention is being paid to reforming healthcare delivery and cost savings by disease prevention,” said M. Rizwan Sohail, M.D., assistant professor of medicine, Mayo Clinic College of Medicine, Rochester, Minn., lead author of the new study. “However, in our current analysis, we have tried to bring the focus back to where it should be, and that is the enormous cost of complications and mortality associated with complex medical procedures. Prevention of these infectious complications can lead to major cost savings and improve survival in this group of patients.”

Key Findings From the Study

• The in-hospital mortality rate for pacemaker and defibrillator implantation admissions, with an infection, was 4.8-7.7-fold the rate for non-infected admissions, depending on the device type.

• The longer-term mortality rate (death during the admission quarter and following year) was 27-35 percent, about 1.6 to 2.1-fold the rate without infection, depending on the device type.

• The mean hospital length of stay (LOS) with infection was 2.5 to 4-fold the length of stay without infection.

• Mean total hospitalization cost for pacemaker and defibrillator patients with infection was 1.4-1.8 fold the cost for those without infection, depending on the type of device. The mean standardized incremental costs related to the treatment of the infection ranged from an average of $16,208 for pacemaker infections to $16,498 for certain types of defibrillators. The Medicare analysis revealed that the cost of managing the most extreme situations exceeded $1 million.

“Pacemaker and [implantable cardiac defibrillator] ICD therapies are invaluable tools in treating heart disease. The ‘2010 American Heart Association/Heart Rhythm Society Scientific Statement on Cardiac Implantable Electronic Device (CIED) Infections and their Management’ identified the need for more precise data on the clinical impact and economic burden of pacemaker and defibrillator infections,” said Daniel Lerner, M.D., chief medical officer of Tyrx Inc. “This large population study in a broad spectrum of patients provides important information on the significant impact that cardiac device infections have on mortality, morbidity, and health care costs. These findings further underscore the need for infection prevention as a key component of the larger health care imperative to reduce mortality, morbidity and health care costs.”

The new study was conducted with financial support from Tyrx Inc. The company commercializes implantable combination drug plus device products focused on infection control, including the AigisRx Antibacterial Envelope and Flat Sheet technologies, designed to reduce surgical-site infections associated CIEDs. AigisRx products contain antimicrobial agents, rifampin and minocycline, which have been shown to reduce infection by organisms representing a majority of the infections reported in implantable pacemaker and defibrillator related endocarditis, including superbugs or MRSA.

For more information: www.tyrx.com

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init